{"id":"licensed-seasonal-influenza-vaccine","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Injection site pain"},{"rate":"15-25","effect":"Injection site erythema"},{"rate":"10-20","effect":"Injection site swelling"},{"rate":"20-30","effect":"Myalgia"},{"rate":"15-25","effect":"Fatigue"},{"rate":"15-25","effect":"Headache"},{"rate":"5-10","effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains recombinant influenza hemagglutinin (HA) protein antigens produced using baculovirus expression technology, combined with Matrix-M adjuvant to enhance immune response. This protein-based approach triggers both humoral and cell-mediated immunity, enabling the body to recognize and neutralize influenza viruses before infection occurs.","oneSentence":"Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:57.854Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of seasonal influenza in adults aged 18 years and older"}]},"trialDetails":[{"nctId":"NCT07464314","phase":"PHASE1","title":"A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in Adults","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-09","conditions":"Influenza, Human+COVID-19","enrollment":225},{"nctId":"NCT05945485","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-10-16","conditions":"Influenza","enrollment":50},{"nctId":"NCT07340047","phase":"PHASE1","title":"H1ssF Flu Vaccine Clinical Trial","status":"NOT_YET_RECRUITING","sponsor":"University of Minnesota","startDate":"2026-08-01","conditions":"Influenza","enrollment":112},{"nctId":"NCT00782431","phase":"PHASE3","title":"Immunogenicity and Safety Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) in Adults Aged 50 Years and Older","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2008-11","conditions":"Influenza","enrollment":3208},{"nctId":"NCT06501963","phase":"PHASE4","title":"Revealing Protective Immunity to Influenza Using Systems Immunology","status":"COMPLETED","sponsor":"Emory University","startDate":"2024-10-14","conditions":"Influenza","enrollment":51},{"nctId":"NCT05755620","phase":"PHASE1","title":"A Study to Evaluate the Safety and Immunogenicity of a Single Dose of H1ssF-3928 mRNA-LNP in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-04-05","conditions":"Influenza","enrollment":50},{"nctId":"NCT06125691","phase":"PHASE1","title":"Safety and Immunogenicity First-in-human Dose-ranging Study of Self-Amplifying RNA Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"Arcturus Therapeutics, Inc.","startDate":"2024-01-22","conditions":"Influenza, Human","enrollment":139},{"nctId":"NCT01773928","phase":"PHASE3","title":"Inactivated Split Virus Seasonal Influenza Vaccine (Vero Cell-Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2013-01","conditions":"Influenza","enrollment":1928},{"nctId":"NCT06680375","phase":"PHASE1","title":"A Study of an Investigational Flu Seasonal/SARS-CoV-2 Combination Vaccine in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-11","conditions":"COVID-19","enrollment":106},{"nctId":"NCT06602024","phase":"PHASE3","title":"A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2024-09-16","conditions":"Seasonal Influenza","enrollment":40817},{"nctId":"NCT05827978","phase":"PHASE3","title":"Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2023-04-17","conditions":"Seasonal Influenza","enrollment":8411},{"nctId":"NCT04583995","phase":"PHASE3","title":"A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom","status":"COMPLETED","sponsor":"Novavax","startDate":"2020-09-28","conditions":"SARS-CoV-2 Infection, COVID-19","enrollment":15185},{"nctId":"NCT04896086","phase":"PHASE1","title":"First-in-Human Clinical Trial of a Mosaic Quadrivalent Influenza Vaccine Compared With a Licensed Inactivated Seasonal QIV in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-05-24","conditions":"Influenza, Seasonal Influenza","enrollment":63},{"nctId":"NCT05566639","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-09-14","conditions":"Seasonal Influenza","enrollment":22502},{"nctId":"NCT05415462","phase":"PHASE3","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-06","conditions":"Seasonal Influenza","enrollment":6102},{"nctId":"NCT05223179","phase":"PHASE1","title":"Intramuscular CodaVax-H1N1 in Healthy Adults","status":"COMPLETED","sponsor":"Codagenix, Inc","startDate":"2022-04-11","conditions":"Influenza, Human","enrollment":69},{"nctId":"NCT03777163","phase":"PHASE4","title":"Safety and Immunogenicity of the Butantan Institute Influenza Vaccine Compared to Sanofi Pasteur Influenza Vaccine","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2019-04-22","conditions":"Influenza","enrollment":632},{"nctId":"NCT05616546","phase":"PHASE4","title":"Bone Marrow and Peripheral Blood Immune Responses Study","status":"RECRUITING","sponsor":"Emory University","startDate":"2023-10-16","conditions":"Influenza","enrollment":90},{"nctId":"NCT05581407","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of TETRALITE, a Novel Adjuvanted, Low-dose Influenza Vaccin","status":"COMPLETED","sponsor":"LiteVax BV","startDate":"2022-10-03","conditions":"Influenza","enrollment":60},{"nctId":"NCT04956575","phase":"PHASE1, PHASE2","title":"A Study of mRNA-1010 Seasonal Influenza Vaccine in Healthy Adults","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2021-07-06","conditions":"Seasonal Influenza","enrollment":885},{"nctId":"NCT04120194","phase":"PHASE3","title":"Phase 3 Pivotal Trial of NanoFlu™ in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2019-10-14","conditions":"Influenza, Human","enrollment":2654},{"nctId":"NCT03658629","phase":"PHASE2","title":"Phase 2 Dose and Formulation Confirmation of Quad-NIV in Older Adults","status":"TERMINATED","sponsor":"Novavax","startDate":"2018-09-24","conditions":"Influenza, Human","enrollment":1375},{"nctId":"NCT04192500","phase":"PHASE2","title":"Safety and Immune Response of One Dose of OVX836 at Two Dose Levels, in Comparison to Influvac TetraTM, After Intramuscular Administration in Healthy Subjects Aged 18-65 Years","status":"COMPLETED","sponsor":"Osivax","startDate":"2019-12-11","conditions":"Influenza","enrollment":300},{"nctId":"NCT01676402","phase":"PHASE1","title":"Seasonal Influenza HA DNA With Trivalent Inactivated Vaccine (TIV) Administered ID or IM in Healthy Adults 18-70 Years","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-08","conditions":"Influenza","enrollment":316},{"nctId":"NCT04548518","phase":"PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Split Virion Influenza Vaccine, in Healthy Thai Elderly","status":"UNKNOWN","sponsor":"Mahidol University","startDate":"2020-08-03","conditions":"Influenza","enrollment":816},{"nctId":"NCT03553940","phase":"PHASE1","title":"H3N2 M2SR in Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-08-15","conditions":"Influenza, Influenza Immunisation","enrollment":43},{"nctId":"NCT00987350","phase":"PHASE4","title":"Safety Study of Seasonal Influenza Vaccine by Jet Injection","status":"COMPLETED","sponsor":"University of Maryland, Baltimore","startDate":"2010-01","conditions":"Healthy Adults","enrollment":60},{"nctId":"NCT04515368","phase":"NA","title":"A Pilot Clinical Study of PET Scanning in Evaluation of Vaccine Reactogenicity","status":"COMPLETED","sponsor":"Imperial College London","startDate":"2016-06-10","conditions":"Positron-Emission Tomography, Immunization Reaction","enrollment":54},{"nctId":"NCT03390166","phase":"PHASE2, PHASE3","title":"Immunogenicity and Safety of Tri Fluvac, a Seasonal Trivalent Inactivated Influenza Vaccine in Healthy Thai Adults","status":"COMPLETED","sponsor":"Mahidol University","startDate":"2017-07-24","conditions":"Influenza","enrollment":945},{"nctId":"NCT03163342","phase":"PHASE4","title":"Immune Response Following Seasonal Influenza Vaccination","status":"COMPLETED","sponsor":"Altimmune, Inc.","startDate":"2017-05-08","conditions":"Influenza","enrollment":20},{"nctId":"NCT01609998","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine & Seasonal Influenza Trivalent Inactivated Vaccine (TIV) in Children & Adolescents","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2012-06","conditions":"Influenza","enrollment":75},{"nctId":"NCT03300362","phase":"PHASE2","title":"Improved Novel VaccIne CombinaTion InflUenza Study","status":"TERMINATED","sponsor":"Barinthus Biotherapeutics","startDate":"2017-10-13","conditions":"Influenza","enrollment":862},{"nctId":"NCT00442975","phase":"PHASE4","title":"Response of Older Adults to Influenza Vaccination With Regard to Cytomegalovirus (CMV) Status","status":"COMPLETED","sponsor":"Public Health England","startDate":"2007-03","conditions":"Influenza","enrollment":100},{"nctId":"NCT02133781","phase":"PHASE4","title":"B-cell Immunity to Influenza (SLVP017)- Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-07","conditions":"Influenza","enrollment":51},{"nctId":"NCT02545543","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 5 Through 17 Years of Age","status":"COMPLETED","sponsor":"Seqirus","startDate":"2015-09","conditions":"Influenza, Human","enrollment":2278},{"nctId":"NCT02141581","phase":"PHASE4","title":"Plasmablast Trafficking and Antibody Response in Influenza Vaccination (SLVP021 2011-2014)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2011-08","conditions":"Influenza","enrollment":86},{"nctId":"NCT03022396","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 2, 2010","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"Influenza","enrollment":82},{"nctId":"NCT01827462","phase":"PHASE4","title":"Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-10","conditions":"Influenza","enrollment":136},{"nctId":"NCT01831934","phase":"PHASE4","title":"Responses to Influenza Vaccine in Patients With Mitochondrial Disorders (MELAS)","status":"COMPLETED","sponsor":"Stanford University","startDate":"2010-09","conditions":"MELAS Syndrome","enrollment":22},{"nctId":"NCT01987349","phase":"PHASE4","title":"T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009","status":"COMPLETED","sponsor":"Stanford University","startDate":"2009-09","conditions":"Influenza","enrollment":72},{"nctId":"NCT00620815","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of a Tetravalent Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-11","conditions":"Influenza","enrollment":601},{"nctId":"NCT01498718","phase":"PHASE1","title":"Seasonal Influenza DNA Vaccine Prime With Trivalent Inactivated Vaccine (TIV) Boost Compared to TIV Alone","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-12","conditions":"Influenza","enrollment":131},{"nctId":"NCT00424086","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived)","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2007-01","conditions":"Influenza","enrollment":1000},{"nctId":"NCT00976469","phase":"PHASE1, PHASE2","title":"A/H1N1 Immunogenicity and Safety in Infants, Children and Adolescents","status":"COMPLETED","sponsor":"Alachua Government Services, Inc.","startDate":"2009-09","conditions":"Influenza, Pandemic Influenza","enrollment":400},{"nctId":"NCT01000584","phase":"PHASE4","title":"Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine","status":"COMPLETED","sponsor":"David Scheifele","startDate":"2009-11","conditions":"Influenza, H1N1 2009 Influenza","enrollment":309},{"nctId":"NCT01173211","phase":"PHASE2","title":"2010-2011 Trivalent Influenza Vaccine (TIV) in Pregnant Women","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2010-09","conditions":"Influenza","enrollment":183},{"nctId":"NCT01209780","phase":"PHASE3","title":"Safety and Immunogenicity of Trivalent Subunit Inactivated Flu Vaccine Administered to Healthy Children and Adolescents 3 to 17 Years of Age","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2010-09","conditions":"Seasonal Influenza","enrollment":3116},{"nctId":"NCT01709019","phase":"PHASE1","title":"RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly","status":"COMPLETED","sponsor":"Novavax","startDate":"2012-10","conditions":"Respiratory Syncytial Virus (RSV)","enrollment":220},{"nctId":"NCT01014806","phase":"PHASE2","title":"Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults","status":"COMPLETED","sponsor":"Novavax","startDate":"2009-11","conditions":"Influenza","enrollment":467},{"nctId":"NCT00943202","phase":"PHASE2","title":"Sanofi Pasteur, TIV + H1N1, Pediatric Population","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-08","conditions":"Influenza","enrollment":531},{"nctId":"NCT00966342","phase":"PHASE1","title":"Rapid Evaluation of Seasonal Influenza Vaccine","status":"WITHDRAWN","sponsor":"University of British Columbia","startDate":"2009-08","conditions":"Influenza","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":5,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Licensed seasonal influenza vaccine","genericName":"Licensed seasonal influenza vaccine","companyName":"Novavax","companyId":"novavax","modality":"Biologic","firstApprovalDate":"","aiSummary":"Novavax's seasonal influenza vaccine stimulates the immune system to produce antibodies and cellular immunity against circulating influenza virus strains. Used for Prevention of seasonal influenza in adults aged 18 years and older.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":3,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}